中蜂越夏及秋季繁殖试验

在贵州锦屏进行的中蜂越夏及秋繁试验表明，４框以上的群势越夏较为安全。越夏期间每框足蜂约需补喂白糖１．５公斤。越夏后，蜂群群势约下降１／３左右。蜂群在越夏期间飞逃的主要原因是缺蜜及巢虫危害。当地中蜂在秋季大流蜜初期发生分蜂，分蜂群势均为８框足蜂以上，７框左右不分群。为控制不同起繁群势的蜂群在秋季大流蜜初期正好繁殖到７框左右，不致因分蜂影响秋冬蜜的采集，应分期起步秋繁。根据本试验所建秋季起繁群势（ｘ）与达７框群势所需繁殖天数（ｙ）之间的回归直线方程推算，在起繁群势为１～５框蜂量时，最适的秋繁开始期，１框群为７月３１日，２框群８月１０日……蜂群的基础群势每增加一框，则秋繁开始期应相应推迟１０～１１天。     

草地早熟禾品种在北京地区对褐斑病的抗性评价

采用田间目测法对草地早熟禾（Poa pratensis）31个品种的抗病性进行评价。结果表明,不同品种（系）对褐斑病（Rhizoctonia solani）的抗性有较明显差异,抗病程度分别从高感到高抗,其中有9个品种的相对抗病指数与隶属函数值均在0.70～1.00,属褐斑病高抗;有6个的相对抗病指数与隶属函数值在0.50～0.70,属于褐斑病中抗;有1个的相对抗病指数与隶属函数值在0.30～0.50,属褐斑病感病;有9个的相对抗病指数与隶属函数值在0.10～0.30,属褐斑病中感;有3个的相对抗病指数与隶属函数值在0.10以下,属褐斑病高感;有3个品种由于评价结果不一致尚不确定其抗病等级。     

三黄白术片对人工感染鸡传染性法氏囊病的疗效

３组１６日龄小鸡人工感染以鸡传染性法氏囊病（ＩＢＤ）病毒,４８ｈ后出现临床症状,分别内服三黄白术片,剂量分别为０．３７５ｇ,０．２５ｇ和０．１２５ｇ,每日２次,连服５日,随后的１０日内,治疗组分别死亡１３．３％（４／３０）、１６．７％（５／３０）和４０％（１２／３０）,而未治疗的对照组死亡５３．３％（１６／３０）。在相对增重上,治疗组分别为７３．９％、７０．１％和７１．１％,而未治疗对照组为２５．８％。     

马立克氏病病毒感染鸡羽髓上皮细胞差异蛋白质组学研究

为鉴定鸡羽髓上皮细胞感染马立克氏病病毒(MDV)前后差异表达的蛋白,本研究以MDV强毒GA株人工感染SPF鸡,并通过双向电泳技术进行分析.结果显示:在病毒感染后4 d、7 d、14 d和21 d显著差异表达的蛋白点分别有2个、8个、25个和9个;而通过质谱技术鉴定出29种蛋白质,其中包括能量代谢相关蛋白、增殖和凋亡相关蛋白、细胞骨架蛋白、信号传导蛋白、转录相关蛋白、免疫相关蛋白和其他功能蛋白质.本实验首次对鸡羽髓上皮细胞感染MDV后各时期蛋白表达水平的变化进行研究,鉴定了多种差异表达蛋白质,为进一步揭示MDV与宿主的相互关系、感染性病毒粒子的成熟和致病机制提供了依据.     

A prospective,randomized, double-blind,placebo-controlled multisite,parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab,a canine anti-nerve growth factor monoclonal antibody

ObjectiveBedinvetmab, a fully canine anti-nerve growth factor monoclonal antibody, was evaluated in dogs for control of osteoarthritis-related pain in a study conducted to support registration in the USA.Study designRandomized, double-blind, placebo-controlled, multicenter, parallel-group study.AnimalsGeneral practice client-owned dogs with osteoarthritis (n = 272).MethodsDogs were block randomized 1:1 to placebo (saline, n = 137) or bedinvetmab (n = 135; 0.5–1.0 mg kg^–1) administered subcutaneously, once monthly. The primary end point, day 28 Canine Brief Pain Inventory (CBPI) treatment success (TS), required pain severity score (PSS; 0–10) decrease ≥1 and pain interference score (PIS; 0–10) decrease ≥ 2. CBPI TS rates [and number needed to treat (NNT)], change in scores [and standardized effect size (ES)], change in quality of life (QoL) and bedinvetmab half-life were calculated.ResultsSignificant (p < 0.05) improvement with bedinvetmab over placebo occurred (days 28, 42, 56, 84) for CBPI TS. Of cases evaluable for day 28 CBPI TS (placebo, n = 131; bedinvetmab, n = 128), success rates were 36.6% and 47.4%, respectively (p = 0.0410) (NNT, 9.3; PSS and PIS ES, 0.3). CBPI TS increased after the second dose in both groups, plateaued for bedinvetmab at day 42 and decreased for placebo beginning day 84. Day 84 NNT (4.3), PSS (0.4) and PIS (0.5) showed continued improvement with monthly dosing. After the first dose, mean (± standard deviation) bedinvetmab half-life was 19.1 (8.3) days. Adverse events were similar between groups and not considered treatment-related. There was a significant effect of bedinvetmab versus placebo on all CBPI components (PIS, PSS, QoL).Conclusions and clinical relevanceThese results corroborated those previously reported and provide further support of safety and effectiveness of bedinvetmab (0.5–1.0 mg kg^–1) administered subcutaneously at monthly intervals to dogs for control of osteoarthritis-related pain.